Agenus posts corporate presentation spotlighting botensilimab-balstilimab neoadjuvant strategy in MSS colon cancer
AGEN•Timing and financing details
Trial start is targeted for the first patient in by Q1 2027; interim pathologic response readout is expected in 2H 2027; interim EFS analysis in 2H 2029.
PIPE financing totals USD 340 million including warrants; upfront USD 85 million at USD 3.69; designed to fund operations through end-2031.
Implied issuance of 78 million new shares across upfront and warrants; 42,680,014 shares outstanding pre-transaction as of July 10, 2026.
Corporate presentation outlines Phase 3 strategy
Agenus outlined a registrational Phase 3 ROBBIN trial of botensilimab with balstilimab in neoadjuvant MSS colon cancer; n=850; primary endpoint event-free survival.
Early investigator studies showed pathologic responses
Two neoadjuvant investigator studies, NEST and UNICORN, in 52 patients showed about in MSS () with .
